

1 **Supplementary appendix**

2 **Supplementary Table 1** Aripiprazole pharmacokinetic parameters after the first and fourth dose of Ari 2MRTU 960 or the first, seventh, and eighth  
 3 dose of AOM 400<sup>24</sup>

| Pharmacokinetic parameter                     | Ari 2MRTU 960                 |                    | AOM 400           |                     |                    |
|---|-------------------------------|--------------------|-------------------|---------------------|--------------------|
|   | First dose (n=38)             | Fourth dose (n=34) | First dose (n=35) | Seventh dose (n=33) | Eighth dose (n=32) |
| <b>AUC<sub>0-56</sub>, ng.day/mL</b>          | 9,180 (4,940) <sup>a</sup>    | 14,700 (7,460)     | ND                | ND                  | ND                 |
| <b>AUC<sub>0-28</sub>, ng.day/mL</b>          | 4,200 (3,000)                 | 7,190 (3,470)      | 5,030 (2,580)     | 7,760 (4,300)       | 7,840 (5,170)      |
| <b>AUC<sub>29-56</sub>, ng.day/mL</b>         | ND                            | 7,500 (4,200)      | ND                | ND                  | ND                 |
| <b>C<sub>max</sub>, ng/ml</b>                 | 286 (203) <sup>a</sup>        | 342 (157)          | 280 (123)         | 339 (168)           | 344 (212)          |
| <b>T<sub>max</sub>, median days (min-max)</b> | 8.58 (3.92-55.9) <sup>a</sup> | 28.0 (0.93-49.0)   | 9.04 (3.83-27.9)  | 6.97 (1.05-28.0)    | 4.07 (0-28.0)      |
| <b>PTF%</b>                                   | ND                            | 63.4 (25.1)        | ND                | ND                  | 48.3 (19.0)        |

4 **Notes:** Data are mean (SD), unless stated otherwise. <sup>a</sup>n=37.

5 **Abbreviations:** AOM 400, aripiprazole once-monthly 400 mg; Ari 2MRTU 960, aripiprazole 2-month ready-to-use 960 mg; AUC<sub>0-28</sub>, area under  
 6 concentration-time curve from Day 0 to Day 28 after study drug administration; AUC<sub>0-56</sub>, area under concentration-time curve from Day 0 to Day  
 7 56 after study drug administration; AUC<sub>29-56</sub>, area under concentration-time curve from Day 29 to Day 56 after study drug administration; C<sub>max</sub>,  
 8 maximum (peak) plasma concentration of the drug; ND, not determined; PTF%, peak-to-trough percent fluctuation; SD, standard deviation; T<sub>max</sub>,  
 9 time to maximum (peak) plasma concentration.

10 **Supplementary Table 2** Aripiprazole pharmacokinetic parameters after the first and fourth dose  
11 of AL 1064<sup>28</sup>

| Pharmacokinetic parameter                     | AL 1064                        |                       |
|---|--------------------------------|-----------------------|
|   | First dose<br>(n=32)           | Fourth dose<br>(n=28) |
| <b>AUC<sub>last</sub>, ng.day/mL</b>          | 3,692.4 (1,900.0)              | 14,188.1 (6,169.5)    |
| <b>AUC<sub>τ</sub>, ng.day/mL</b>             | 3,945.0 (2,078.1) <sup>a</sup> | 7,880.0 (3,208.7)     |
| <b>C<sub>max</sub>, ng/ml</b>                 | 129.6 (62.7)                   | 188.8 (79.8)          |
| <b>T<sub>max</sub>, median days (min–max)</b> | 43.4 (30–56)                   | 34.4 (0–63)           |

12 **Notes:** Data are mean (SD), unless stated otherwise. <sup>a</sup>n=19.

13 **Abbreviations:** AL 1064, aripiprazole lauroxil 1064 mg; AUC<sub>last</sub>, area under concentration-time  
14 curve from time zero until the last measurable plasma drug concentration time point; AUC<sub>τ</sub>, area  
15 under concentration-time curve over the dosing interval; C<sub>max</sub>, maximum (peak) plasma  
16 concentration of the drug; SD, standard deviation; T<sub>max</sub>, time to maximum (peak) plasma  
17 concentration.